Circulating microRNA as predictors for exercise response in heart failure with reduced ejection fraction

Eur J Prev Cardiol. 2021 Dec 29;28(15):1673-1681. doi: 10.1093/eurjpc/zwaa142.

Abstract

Aims: Exercise training is a powerful adjunctive therapy in patients with heart failure with reduced ejection fraction (HFrEF), but ca. 55% of patients fail to improve VO2peak. We hypothesize that circulating microRNAs (miRNAs), as epigenetic determinants of VO2peak, can distinguish exercise responders (ER) from exercise non-responders (ENR).

Methods and results: We analysed 377 miRNAs in 18 male HFrEF patients (9 ER and 9 ENR) prior to 15 weeks of exercise training using a miRNA array. ER and ENR were defined as change in VO2peak of >20% or <6%, respectively. First, unsupervised clustering analysis of the miRNA pattern was performed. Second, differential expression of miRNA in ER and ENR was analysed and related to percent change in VO2peak. Third, a gene set enrichment analysis was conducted to detect targeted genes and pathways. Baseline characteristics and training volume were similar between ER and ENR. Unsupervised clustering analysis of miRNAs distinguished ER from ENR with 83% accuracy. A total of 57 miRNAs were differentially expressed in ENR vs. ER. A panel of seven miRNAs up-regulated in ENR (Let-7b, miR-23a, miR-140, miR-146a, miR-191, miR-210, and miR-339-5p) correlated with %changeVO2peak (all P < 0.05) and predicted ENR with area under the receiver operating characteristic curves ≥0.77. Multiple pathways involved in exercise adaptation processes were identified.

Conclusion: A fingerprint of seven miRNAs involved in exercise adaptation processes is highly correlated with VO2peak trainability in HFrEF, which holds promise for the prediction of training response and patient-targeted exercise prescription.

Keywords: Exercise training; Heart failure; MicroRNA; Pathways; Response; VO2peak.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Circulating MicroRNA* / blood
  • Exercise Therapy*
  • Heart Failure* / genetics
  • Heart Failure* / therapy
  • Humans
  • Male
  • Oxygen Consumption
  • Stroke Volume

Substances

  • Circulating MicroRNA
  • Mirn140 microRNA, human